Sensiva Health, an infection prevention and precision medicine-driven healthcare solutions company, announced on Tuesday the appointment of Donovan Blakney as chief operating officer (COO), effective immediately.

In this role, Blakney's priorities include enhancing operational scalability and expanding innovative programs such as Sensiva Shield, while advancing next-generation sequencing (NGS) genetics, toxicology, and pharmacogenomics (PGx) service lines, preparing for advanced genetic cancer testing in January 2026, and ensuring seamless delivery of Sensiva services across laboratory, distribution, and technology operations.

Blakney has experience in direct-to-consumer and healthcare operations, with a proven track record at Sensiva Health. He joined the company as director of operations in 2020 and advanced to vice president of operations.

According to Sensiva, Blakney has played a pivotal role in driving operational excellence across the company's laboratory, software, manufacturing, and distribution verticals. He led efforts to launch Sensiva's medical device facility and distribution network, and his expertise in scaling operations, managing internal and external teams, and bridging customer needs with enterprise service lines will be instrumental in advancing the company's evolving mission.